When: Price rejection at $104-107 on volume

Then: Enter tactical short 1-2% portfolio notional

When: Price breakdown below $97.94 on volume

Then: Enter tactical short 1-2% portfolio notional

TRIM existing ABT exposure by 25% (not 40%) into $104-$107 zone; DO NOT initiate tactical short at current levels; wait for resistance rejection or breakdown below $97.94 before escalating

• Treasury yield comparison is flawed: ABT's 2.49% yield is not equivalent to 4.5-5% 10-year; dividend has 54-year track record of increases unlike fixed-coupon Treasuries
• Integration risk argument supports trim, not short: $35B goodwill and $27B net debt with 13% correction already prices in meaningful skepticism
• Forward P/E around 16.7 on consensus $6.07 earnings already discounts integration concerns at current $101 price
• Technical setup favors patience: RSI at 36 approaching oversold, three failed bounces in low-beta (0.586) stock has not broken lower Bollinger band
• Reject tactical short: stop above $108 in a low-beta defensive compounder with dividend floor creates unfavorable expected value
• Wait for confirmation: no action on short until close below $97.94 or resistance rejection at $104-$107
• Reddit silence is uninformative, not bearish: $175B market cap healthcare giant trades on fundamentals and institutional flows, not retail chatter

→ vs aggressive: Treasury comparison breaks down immediately—ABT 2.49% vs 10-year at 4.5-5% are not equivalent; 54-year dividend track record adds value Treasuries cannot offer

→ vs aggressive: Short with $108.50 stop in a 0.586 beta stock with dividend floor and just-cleared $385M litigation overhang has fat left tail not properly priced

→ vs aggressive: Three failed bounces in low-beta stock during high volatility is textbook relief bounce setup, not guaranteed breakdown; waiting for close below $97.94 is discipline not anxiety

→ vs aggressive: Zero Reddit posts is uninformative for a $175B healthcare giant—not a bearish signal; absence of retail buzz means stock trades on fundamentals where compounders find floors

→ vs aggressive: 13% correction with 0.586 beta in flat market is discounting mechanism working, not negative beta—the question is whether it has discounted enough

→ vs neutral: Hold instinct reflects patience that keeps firms solvent when obvious trades feel terrifying; this discipline is a feature, not a weakness

Trim 25% of existing ABT exposure into the $104 to $107 zone using 200 SMA at $103.72 as first execution level and 50 SMA at $107 as upper bound. Do not initiate tactical short at current levels. Wait for price action triggers: add 1% portfolio short only on $104-$107 rejection with $108.50 stop; escalate trim and short aggression on break below $97.94. Redeploy trim proceeds into cleaner technical names or Treasury sleeve.

• Trim 25% of existing ABT exposure into the $104 to $107 zone (not 40%)
• 10-year Treasury yield in 4.5-5% range vs ABT 2.49% yield = ~200 basis point gap still exists, not obliterated
• 54-year track record of dividend increases distinguishes ABT from Treasuries
• Debt-to-equity at 63%, up from ~25% pre-deal = leverage overhang in zero-cut regime
• ABT at 16.7x forward earnings already partially discounting integration risk
• EPS range of $5.00 to $6.07 has wide variance; bear case $5.00 should be treated as tail not base case
• 27 million share distribution event September 18 plus continued elevated selling September 23 confirms institutional sellers working stock lower
• Beta 0.586 provides limited defensive floor given leverage deterioration
• ABT will underperform in risk-on rally and likely not fully participate in defensive bid due to leverage overhang
• 1% portfolio short sizing appropriate if triggered; not at current levels
• First execution level: 200 SMA at $103.72; upper bound: 50 SMA at $107
• Short stop level: $108.50
• Escalation trigger: close below $97.94
• 13% correction already occurred; trim captures value above current levels
• Conservative analyst anchoring on $97.94 round number while price/volume already confirming bear thesis

→ vs aggressive: Treasury comparison overreach: 200 basis point yield gap still exists; 54-year dividend growth history vs Treasury zero growth; ignores inflation hedge component; treating bear tail as base case when EPS variance spans $5.00 to $6.07

→ vs conservative: Defensive floor overreach: ignores 27M share distribution event volume signature of institutional sellers; $97.94 technical level is round-number anchoring while price/volume already confirm bear thesis; 63% debt-to-equity is not a defensive balance sheet in zero-cut regime with 30-year at multi-year highs